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over the past three decades, much prog-ress has been made in reducing deaths from cancers for which preventive strate-
gies are available. Most strikingly, mortality rates 
have dropped between 20 and 50% for cancers 
of the breast, cervix, colon, lung, and prostate 
(SEER, 2012). Conversely, the death rate from 
melanoma has remained remarkably stubborn, 
the product of two divergent trends: rising mela-
noma mortality rates for Americans aged 60 years 
and above, especially among men, countered by 
falling melanoma mortality rates for nearly all age 
groups below 60 years (SEER, 2012). Melanoma 
was once a rare disease, with fewer than 2 cases 
per 100,000 in the 1950s, compared with more 
than 25 cases per 100,000 today (SEER, 2012). 
It is now the fifth most common cancer in US 
men and the cause of more than 9,000 American 
deaths each year (SEER, 2012).
Until recently, doctors have had little to offer 
to improve the survival of patients with meta-
static melanoma. Likewise, the medical and 
public health communities have had insufficient 
evidence supporting the value of melanoma 
screening to persuade the US Preventive Service 
Task Force (USPSTF) of its merit. However, in the 
past watershed year, major developments have 
impacted both ends of the melanoma disease 
spectrum. For advanced melanoma, the approv-
al of two new drugs—Yervoy and Zelboraf—has 
ushered in a new era in therapy (Sondak and 
Flaherty, 2011; Luke and Hodi, 2012). These 
drugs, which attack specific targets in appro-
priately selected tumors on the one hand while 
bolstering the immune response to melanoma 
on the other, not only are helping many patients 
but are also paving the way for even more effec-
tive combination therapies. On the prevention 
end, a public health experiment in Germany has 
breathed new life into the prospects for popu-
lation-based melanoma screening (Katalinic et 
al., 2012). In Schleswig-Holstein (SH), the north-
ernmost German state (population 2.8 million), 
melanoma mortality dropped 40% after a pop-
ulation-wide screening program in which an 
estimated 20% of individuals aged 20 years and 
older were screened. By comparison, melano-
ma mortality in nearby Denmark and the rest of 
Germany changed little during the same period 
(2000–2009) (Katalinic et al., 2012).
The success of the SH experiment can be 
attributed to the collective commitment of 
many, including the more than 1,000 derma-
tologists, general practitioners, and other 
physicians who participated in an eight-hour 
training program, as well as the more than 
360,000 German residents who underwent 
screening. Involvement by the German govern-
ment, federal insurers, and the local media was 
also critical. In addition, the charismatic and 
untiring leadership of the Arbeitsgemeinschaft 
Dermatologische Prävention, or “Working 
Group on Dermatological Prevention,“ was 
paramount in its success. The extension of 
the SH screening program to the remainder 
of Germany bears a striking resemblance to 
organized efforts in Scandinavian countries to 
introduce the Pap smear to a largely unscreened 
populace in the 1960s. Although the impact 
of melanoma screening in Germany may fail 
to mirror the precipitous 90% drop in cervical 
cancer mortality (Sigurdsson, 1999) witnessed 
in Scandinavia over the first 20 years of screen-
ing, if the SH experience is replicated across the 
country, it will be a ringing endorsement of the 
value of screening. In comparing the German 
melanoma experience with the Scandinavian 
cervical cancer experience, it is important to 
note that a sustained, concerted effort spear-
headed by local and community-wide public 
health officials was required to achieve a >85% 
rate of screening of women aged 18 years and 
older in many parts of Scandinavia.
In light of the size of the impact observed 
in SH, we can anticipate the probability of a 
positive outcome for the nationwide experi-
ment in Germany. Analogous to cervical cancer 
screening, given the relatively low costs and 
morbidity associated with melanoma screening, 
The Ever-Evolving Landscape for Detection  
of Early Melanoma: Challenges and Promises
Journal of Investigative Dermatology (2013) 133, 583–585. 
doi:10.1038/jid.2012.360
editorial
584 Journal of Investigative Dermatology (2013), Volume 133 
a strong trend in reduced mortality in response to the screen-
ing should translate into a mandate for population-based 
screening in the United States. It is therefore imperative 
that we begin to address the major challenges to melanoma 
screening in the United States.
First, we must commit to crafting a national plan to 
reduce melanoma deaths to well below the rates we see 
today. Critical participants are already in place: more than 
750,000 melanoma survivors and their estimated 2 mil-
lion first-degree family members; organizations such as 
the American Academy of Dermatology, the American 
Cancer Society, and the National Council of Skin Cancer 
Prevention; foundations; and the National Cancer Institute 
and Centers for Disease Control and Prevention.
The screening effort in Germany was fueled by a 
creative outreach campaign coupled with nearly univer-
sal physician training and led by unprecedented funding 
mechanisms. The many unanswered questions for the dis-
semination of such a program in the United States include 
who will pay, who will do the screening, and whether visu-
al examinations should be bolstered by new technologies.
Central to the plan are three long-term imperatives: (i) 
teach the basic, integrated skin examination to previously 
untrained physicians and physician extenders; (ii) screen 
high-risk unscreened individuals; and (iii) conduct the req-
uisite research to quantify the risks and benefits of screen-
ing and inform screening strategies. Although persons of low 
socioeconomic status and white middle-aged and older men 
are at increased risk of fatal melanoma, they are the least like-
ly to report having been screened. In fact, more than 50% of 
melanoma deaths are in white men 50 years of age and older 
(SEER, 2012), but only 16% have ever been screened (Coups 
et al., 2010). Lessons can be learned from our colleagues, 
policy makers, and women’s groups who have spearheaded 
efforts resulting in 80% of US women 50 years of age and 
older undergoing mammographic screening. Although most 
melanoma patients have seen their primary-care physician in 
the year before diagnosis, they often report that they were not 
screened for melanoma (Geller et al., 1992).
Although melanoma “writes its message in the skin for 
all of us to see” (Davis, 1988), formal training in melanoma 
detection is clearly needed. By extracting the best parts of 
the eight-hour mandatory continuing medical education 
course for German physicians and combining it with the 
US INFORMED (Shaikh et al., 2012) Web-based curricu-
lum, we can produce a masterful and engaging Web-based 
skin cancer teaching program that can be rigorously tested 
for internists, nurse practitioners, and physician assistants. 
A recent editorial in the New England Journal of Medicine 
(Prober and Heath, 2012) called for similar teaching tech-
niques for medical students. Bold and innovative success-
es from the Khan Academy and its online library resource 
of more than 3,300 educational videos show promise for 
teaching and disseminating new information. And the 
use of such technology as teledermatology, total-body 
photography, and digital dermoscopy, which improve 
sensitivity while achieving low benign:malignant biopsy 
rates, must be incorporated into new teaching.
Second, incorporating new policy initiatives is para-
mount. The USPSTF recently gave a B-level recommenda-
tion for behavioral counseling to prevent skin cancer in 
patients 10 to 24 years old, an upgrade from the previous 
I rating (insufficient evidence) (Moyer, 2012). Such ratings 
indicate at least fair evidence that the service improves 
important health outcomes and concludes that benefits 
outweigh harms. Results from the well-executed German 
screening and educational program (albeit not a random-
ized study) should now be proactively shared with the 
USPSTF, which has previously argued that there is insuf-
ficient evidence to support the recommendation of popu-
lation-based skin cancer screening (Wolff et al., 2009; US 
Preventive Services Task Force, 2009). In its most recent 
report on screening, the USPSTF noted that “no studies 
of the benefits of screening have compared a screened 
population with an unscreened population with respect 
to appropriate health outcomes” (US Preventive Services 
Task Force, 2009). If, indeed, the new evidence from the 
SH experiment in Germany results in revised guidelines, 
previously unforeseen possibilities emerge. For example, 
the skin cancer examination could be integrated into the 
wellness and preventive services prevention package due 
to go into effect as part of the Affordable Care Act by 2014. 
A significant economic barrier might also be lifted because 
patients would no longer be subject to deductibles for pre-
ventive services and physicians could seek reimbursement 
for the opportunistic examination.
Third, recognizing the limitations of the Germany experi-
ment and the need for formal studies of melanoma screening, 
supporting and adopting new screening guidelines could 
pave the way for closed health-care systems and account-
able-care organizations to consider implementation of 
formal studies of the risks, benefits, and cost-effectiveness 
of screening. Ideally, a randomized clinical trial of screen-
ing would be conducted. Unfortunately, however, the 
costs of such a study, especially in the current political and 
economic climate, may be prohibitive. For example, the 
cost of one proposed study—a five-year screening study 
involving 350,000 intervention and 700,000 control sub-
jects and 12 years of follow-up—was estimated to be $70 
million (Geller, 2009).
Prior to the launch of a national population-based 
screening trial, various components of the model should 
be pilot-tested in a stepped and coordinated fashion. Large 
numbers of physicians will need to be trained in the basic, 
integrated skin exam, and strategies to encourage partici-
pation must be developed. Physician extenders, such as 
physician assistants, nurses, nurse practitioners, and der-
matology nurse practitioners, would also be important 
candidates for training as well as for participating in con-
trolled studies evaluating online versus in-person training. 
The next steps would be to fine-tune patient recruitment 
and outreach strategies, test the new technologies, and 
devise a follow-up protocol. The resulting strategies could 
be piloted and demonstrated with those at highest risk 
for melanoma, such as first-degree relatives of melanoma 
patients and individuals with multiple atypical moles.
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A study of potential harms of screening is key—although 
the USPSTF has expressed concern that false-positive 
results may lead to biopsies and unnecessary treatment, 
they have acknowledged that the evidence to back up this 
theory is limited (Wolff et al., 2009). Screening should be 
lodged within closed health-care systems that have experi-
ence in large screening trials and the demonstrated ability 
to follow up on all participants. They would also need to be 
capable of capturing melanoma thickness, mortality, and 
other relevant data. In addition, there may be the poten-
tial to seek funding for a Medicare demonstration project, 
possibly in a state with high melanoma mortality rates and 
physician networks lodged in underserved areas. Lessons 
can be learned on obtaining cost estimates for broad-scale 
public health efforts from the Assessing Cost-Effectiveness–
Obesity group and its important contribution to obesity-
prevention programs (Carter et al., 2009).
Finally, maximal resources from cancer-control orga-
nizations, including those in the United States, Germany, 
and the rest of Europe, should be devoted to optimizing 
data collection in these and comparator nations. The SH 
population-based screening program described above 
was a precursor to a large and expansive ongoing effort 
throughout Germany. To date (from 1 July 2008 through 1 
July 2012), more than 75% of the general practitioners and 
dermatologists in Germany have completed the mandatory 
eight-hour training program, and more than 20 million 
screenings of individuals aged 35 years and older have 
been performed. Studies comparing melanoma mortality 
rates; evaluating tumor thickness in all cases diagnosed 
before, during, and after screening; and analyzing the costs 
of screening should be conducted in Germany and the 
results compared with those in neighboring nations.
In summary, in the United States, melanoma remains 
the only preventable cancer for which mortality rates are 
not dropping (SEER, 2012; Coups et al., 2010; Centers for 
Disease Control and Prevention, 2012). Nevertheless, pop-
ulation-wide screening rates remain low. As melanoma rates 
continue to rise and patient demand for screening acceler-
ates, the current deficit in the dermatology workforce will 
become even more apparent. However, a confluence of new 
developments holds much promise. Web-based technol-
ogy affords the potential to teach standardized skin cancer 
examinations to physicians, physician extenders, and high-
risk patients in multiple settings. Digital dermoscopy offers 
clinicians new options for distinguishing between benign, 
atypical, and aggressive lesions. The Affordable Care Act has 
the promise of providing screenings to the majority of the 
US high-risk population that has yet to be screened. Finally, 
the results of the German screening program provide new 
and important evidence for the value and benefits of visual 
examination for melanoma.
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